Christopher Yea has sold KALV and made no open-market buys since Jan 2019
Chief Development Officer at KalVista Pharmaceuticals, Inc.
SEC CIK 0001691102 · Filings on SEC.gov ↗
Every filing
26 filings since Jan 2019, newest first
KalVista Pharmaceuticals, Inc.
Chief Development Officer
KalVista Pharmaceuticals, Inc.
Chief Development Officer
KalVista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
Kalvista Pharmaceuticals, Inc.
Chief Development Officer
About Christopher Yea
Christopher M. Yea, PhD is the Chief Development Officer at KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), where he is responsible for all development-related activities across the company’s pipeline of small-molecule protease inhibitors.( In this role, he oversees the progression of drug candidates from research into and through clinical development, supporting KalVista’s strategy as a clinical-stage pharmaceutical company.( As a corporate insider, Yea has been involved in equity transactions in KalVista stock, including option exercises and share sales reported in regulatory filings.(
Yea is a biochemist by training, holding both a BSc and PhD in Biochemistry from the University of Bristol in the United Kingdom.( Following post‑doctoral research, he spent several years at Roussel‑UCLAF and Hoechst Marion Roussel before joining Ferring Pharmaceuticals, where he led the Biology group and was responsible for transitioning candidates into development.( In 2008, he co‑led the spin‑out of Vantia Ltd and later served as its Chief Operating Officer, overseeing development programs through Phase 3 clinical trials.( This combination of industry, leadership, and late‑stage development experience underpins his role guiding KalVista’s development organization.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.